Looking for Kinetico Water Systems? Click Here!

Commercial Strategy Biopharmaceutical Practice

Our Commercial Strategy services help biopharmaceutical companies maximize the commercial value of their products across all phases of the product lifecycle.

Service lines include:

Business Model Design

  • Commercialize vs. Partner
  • Regional Strategies
  • Cost / Benefit and ROI Analysis

Market Access

  • Payer Interviews
  • Health Economics (HECON) / Real World Evidence (RWE) Analysis
  • Pricing / Discount Strategies
  • Benchmarking

Forecasting

  • Scenario-based Financial Models
  • Key Assumption Development
  • Peak Year and Beyond Forecasts


Click the Tabs Below for Commercial Strategy Case Studies

 

Business Model Design

Situation: A specialty pharmacy company focused on rare hematological disorders needed support and guidance establishing their ex-US commercialization strategy.  The sponsor had recently experienced a successful US launch but required support evaluating commercialization models for Canada.  The sponsor established some foundational assumptions regarding the market opportunity but needed specific expertise to tease out the unique market factors in order to quantify the opportunity and determine whether to build a commercial infrastructure or to partner the drug.

Click here for the full case study including example deliverables.


Market Access

Situation: A multinational pharmaceutical company with broad manufacturing capabilities was considering horizontally expanding their portfolio to include biosimilars.  Kineticos was charged with providing a detailed analysis of the market opportunity for two unique biosimilar licensing opportunities, as well as any gaps with respect to resource requirements that such an expansion would necessitate.

Click here for the full case study including example deliverables.


Forecasting

Situation: A publicly traded Oncology company with 3 technology platforms and limited resources was in need of narrowing their indication focus.  Their next generation cancer vaccine technology demonstrated early proof of principle in 14 unique tumor types and retained Kineticos to conduct an indication prioritization exercise.  The primary objective of the engagement was to objectively select 2-5 scientifically promising tumor types that also presented commercial opportunity and aligned with the firm’s corporate strategy.

Click here for the full case study including example deliverables.

 

Subscribe to our internal think tank, Kineticos Research Institute